Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

737.50

-12.01

(-1.60%)

As of 09:42AM EST. Market open.

Trade prices are not sourced from all markets

All

Investor's Business Daily
BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug
BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted.
- FDA approves BridgeBio’s Attruby for ATTR-CM treatment
  Pharmaceutical Technology
- BridgeBio Soars After Drug Gets Nod in Rare Heart Condition
  Bloomberg
Premium
MT Newswires
Intellia Therapeutics' Nex-z Receives FDA Regenerative Medicine Advanced Therapy Designation
Intellia Therapeutics (NTLA) said Monday that the US Food and Drug Administration has granted regenerative medicine advanced therapy designation to nexiguran ziclumeran for the treatment of hereditary transthyretin amyloidosis with polyneuropathy.